文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

骨转移来源的免疫细胞中TIGIT轴及CD39/CD73嘌呤能信号通路的表达

Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells.

作者信息

Brauneck Elias, Leonhardt Leon-Gordian, Assemissen Anne Marie, Wahid Yagana, Kruppa Moritz, Kruppa Niklas, Krüger Julius, Menzel Stephan, Koch-Nolte Friedrich, Kylies Julian, Weisel Katja, Bokemeyer Carsten, Wellbrock Jasmin, Fiedler Walter, Viezens Lennart, Brauneck Franziska

机构信息

Division of Spine Surgery, Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

出版信息

Cancer Immunol Immunother. 2025 Apr 24;74(6):182. doi: 10.1007/s00262-025-04030-2.


DOI:10.1007/s00262-025-04030-2
PMID:40274631
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12022200/
Abstract

BACKGROUND: Bone metastases (BM) represent one of the most common sites of metastasis. The study aimed to compare the composition of immune cell infiltration from aspirates of different BM prior to systemic therapy. METHOD: Phenotypic and functional analyses were conducted via multiparametric flow cytometry (MFC) on BM-derived aspirates obtained from patients with breast cancer (BC, n = 6), patients with prostate cancer (PC, n = 5), patients with non-small-cell lung cancer (NSCLC) (n = 7), patients with myeloma (MM, n = 10) and bone aspirates from age-matched non-malignant controls (NMC, n = 10). RESULTS: Across all tumors aspirates the fraction of CD8 T cells was reduced. In contrast, infiltration by immunosuppressive CD56CD16NK and CD163CD86 M2-like macrophages was increased in BM compared to NMC aspirates. BM-derived CD8 T cells aberrantly co-expressed TIGIT with PVRIG or CD39. Similarly, BM-derived cytotoxic NK cells co-expressed TIGIT and PVRIG. In addition, BM-derived M2-like macrophages exhibited an increased subset of cells co-expressing either TIGIT and PVRL4 or CD112 and CD155. Using a myeloma model, functional in vitro studies showed that blockade of TIGIT and CD39 leads to increased PBMC-mediated lysis of myeloma cells. CONCLUSION: The study shows that an altered immune cell composition is present in BM across the different tumor entities. Additionally, molecules of the TIGIT checkpoint as well as of the purinergic pathway are aberrantly expressed by BM-infiltrating CD8 T cells, NK cells and macrophages and also functionally relevant for tumor cell lysis.

摘要

背景:骨转移(BM)是最常见的转移部位之一。本研究旨在比较全身治疗前不同骨转移抽吸物中免疫细胞浸润的组成。 方法:通过多参数流式细胞术(MFC)对来自乳腺癌(BC,n = 6)、前列腺癌(PC,n = 5)、非小细胞肺癌(NSCLC)(n = 7)、骨髓瘤(MM,n = 10)患者的骨转移抽吸物以及年龄匹配的非恶性对照(NMC,n = 10)的骨抽吸物进行表型和功能分析。 结果:在所有肿瘤抽吸物中,CD8 T细胞比例降低。相比之下,与NMC抽吸物相比,BM中免疫抑制性CD56CD16NK和CD163CD86 M2样巨噬细胞的浸润增加。BM来源的CD8 T细胞异常共表达TIGIT与PVRIG或CD39。同样,BM来源的细胞毒性NK细胞共表达TIGIT和PVRIG。此外,BM来源的M2样巨噬细胞中同时共表达TIGIT和PVRL4或CD112和CD155的细胞亚群增加。使用骨髓瘤模型进行的体外功能研究表明,阻断TIGIT和CD39可导致PBMC介导的骨髓瘤细胞裂解增加。 结论:该研究表明,不同肿瘤实体的BM中存在免疫细胞组成改变。此外,TIGIT检查点分子以及嘌呤能途径分子在BM浸润的CD8 T细胞、NK细胞和巨噬细胞中异常表达,并且在功能上与肿瘤细胞裂解相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/b011e8891b84/262_2025_4030_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/42afa99d17a8/262_2025_4030_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/13e8d2c710d5/262_2025_4030_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/328534099533/262_2025_4030_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/e8669f408964/262_2025_4030_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/b011e8891b84/262_2025_4030_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/42afa99d17a8/262_2025_4030_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/13e8d2c710d5/262_2025_4030_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/328534099533/262_2025_4030_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/e8669f408964/262_2025_4030_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21ac/12022200/b011e8891b84/262_2025_4030_Fig5_HTML.jpg

相似文献

[1]
Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells.

Cancer Immunol Immunother. 2025-4-24

[2]
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

Cancer Immunol Immunother. 2011-6-3

[3]
Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML.

Int J Mol Sci. 2021-11-29

[4]
synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.

Nat Commun. 2024-3-1

[5]
Increased frequency of TIGITCD73-CD8 T cells with a TOX TCF-1low profile in patients with newly diagnosed and relapsed AML.

Oncoimmunology. 2021-6-21

[6]
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.

J Immunother Cancer. 2020-5

[7]
Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Cancer Immunol Res. 2014-11-17

[8]
Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73 Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes.

Cells. 2020-7-22

[9]
Regulatory role of CD39 and CD73 in tumor immunity.

Future Oncol. 2024

[10]
CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function.

Purinergic Signal. 2014

本文引用的文献

[1]
Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

Front Immunol. 2024

[2]
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.

Exp Hematol Oncol. 2024-10-28

[3]
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Ann Oncol. 2024-12

[4]
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet. 2024-9-28

[5]
Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer.

Front Immunol. 2024

[6]
Changes in subset distribution and impaired function of circulating natural killer cells in patients with colorectal cancer.

Sci Rep. 2024-5-28

[7]
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.

Oncoimmunology. 2024

[8]
CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.

Curr Med Chem. 2024

[9]
Generation and characterization of antagonistic anti-human CD39 nanobodies.

Front Immunol. 2024

[10]
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2024

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索